Lataa...
Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial
INTRODUCTION: Dulaglutide is a recombinant glucagon-like peptide-1 immunoglobulin G4 Fc fusion protein approved for treating patients with type 2 diabetes (T2D). The aim of this study was to assess postprandial data over 4 weeks for dulaglutide (0.75 mg) versus placebo after a standardized test meal...
Tallennettuna:
| Julkaisussa: | Diabetes Ther |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer Healthcare
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6531535/ https://ncbi.nlm.nih.gov/pubmed/30949907 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-019-0605-7 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|